Thalassemia Treatment Market Global industry analysis from to 2022-2030 explored in latest research and Emerging Trends Future Lookout

Thalassemia Treatment Market: Snapshot

The global thalassemia treatment market is pegged to gain significant amount in the form of revenues during the forecast period of 2018 to 2026. One of the major reasons for this prodigious growth is considerable growth in the number of altered thalassemia genes in people from all worldwide locations. Thalassemia is a genetic disorder related to blood. In this disease, patient’s body is not able to produce normal hemoglobin and manufactures a huge number of abnormal red blood cells, which are continuously destroyed. As a result, an individual becomes anemic.

Get the sample copy of report@ https://qyresearchmedical.com/sample/112003

The segmentation of the global thalassemia treatment market is performed on the basis of treatment type and region. Among all treatment options, blood transfusion and chelation therapy are the most popular options used in treating thalassemia patients. Key reasons for this popularity are the cost-effectiveness and easy accessibility than bone marrow transplantation.

The global market for thalassemia treatment is witnessing stupendous growth avenues due to significant growth in the number of blood transfusion and chelation therapy treatments. Apart from this, increased number of bone marrow transplants, rise in number of spleen surgeries, and increased investments in research and development activities are some of the key factors stimulating the growth of the global thalassemia treatment market.

The global thalassemia treatment market is fairly fragmented in nature. Presence of many well-established enterprises connotes high competitive landscape of the market for thalassemia treatment. To lead in this competition, companies working in the thalassemia treatment market are executing various strategic moves such as collaborations and partnerships. Apart from this, they are focused on incorporation of technological advancements in their work processes. A case in point here is recent collaboration announcement by Novartis and Microsoft. Through this collaboration, Microsoft will help Novartis in its medicine transformation using artificial intelligence. Thus, this collaboration will impact positively on the growth of the global thalassemia treatment market in the upcoming period.

View full report@ https://qyresearchmedical.com/report/thalassemia-treatment-market-treatment-type-blood-transfusion-chelating-therapy-bone-marrow-transplant-and-others-surgery-general-medicines-global-industry-analysis-size-share-growth-trends-and-fore-018-2030/112003

Thalassemia Treatment Market – Snapshot

The global thalassemia treatment market is driven by increase in number of altered thalassemia genes across the globe. The global market was valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026 to reach US$ 1,639.6 Mn by 2026. The global market is witnessing high growth owing to increase in blood transfusion and chelation therapy treatments, high number of bone marrow transplants, increase in number of spleen surgeries, and surge in R&D expenditure.

Thalassemia is a genetic blood disorder which produces abnormal hemoglobin in the body. This genetic blood disorder leads to the formation of a large number of red blood cells that are continuously destroyed, which further leads to anemia. The two types of proteins present in the blood of thalassemia patients are alpha globin and beta globin. Alpha thalassemia occurs primarily in people living in Southeast Asia, the Middle East, China, and Africa. Beta thalassemia occurs in people in the Mediterranean origin, and to a lesser extent in people in China, other Asians, and African Americans. Chelation therapy and blood transfusion are the most common treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion technique for purifying blood increase the possibility of curing thalassemia patients.

Blood transfusion helps patients suffering from alpha thalassemia or beta thalassemia. The transfusion treatment procedure improves overall operational efficiency. High prevalence and incidence rates of thalassemia and rise in number of stem cell transplantations among the global population have resulted in increase in patient flow to private clinics and hospitals. These factors are projected to drive demand for blood transfusion procedure for thalassemia treatment in the near future. Moreover, advancements in gene therapy such as gene editing, stem cell therapy, and proliferation of new drugs for thalassemia treatment are anticipated to fuel the growth of the global thalassemia treatment market from 2018 to 2026.

The global thalassemia treatment market has been segmented based on treatment type and region. In terms of treatment type, the global market has been categorized into blood transfusion, chelating therapy, bone marrow transplant, and others. The chelation therapy segment accounted for major share of the global market in terms of revenue in 2017. The segment is projected to expand at an exponential growth rate during the forecast period. Blood transfusion offers several advantages over bone marrow transplantation such as low cost of treatment. Hence, blood transfusion is gaining popularity among thalassemia patients.

Geographically, the global thalassemia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to lose market share between 2018 and 2026. The market in North America is primarily driven by rapidly increasing immigrant population from tropical regions, growing number of population with thalassemia carrier gene, and rise in birth rates due to variation of genes among the population in the U.S. Moreover, increase in same community marriage practices and high birth rate of alpha thalassemia patients have been observed in Asia Pacific. This is projected to increase adoption of blood transfusion and chelation therapy treatments during the forecast period. Middle East & Africa is projected to be the fastest growing market for thalassemia treatment during the forecast period. Rest of Middle East & Africa dominated the thalassemia treatment market in the region, while the market in GCC Countries is estimated to expand at an exponential CAGR during the forecast period.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112003/2900

Companies such as bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, and Shire plc (Takeda Pharmaceuticals) accounted for the major share of the global thalassemia treatment market in 2016. Celgene Corporation has provided over 525,000 patients with the prescribed Luspatercept medicine. In 2017, the company accelerated 160 trials in approximately 60 indications and more than 25 new molecules have entered preclinical or phase 1 development. Other global players operating in the market include Incyte Corporation, Kiadis Pharma, Gamida Cell, and Bellicum Pharmaceuticals. Companies are adopting the strategy of acquisition and collaboration with parallel companies to improve and strengthen geographic presence in the international market. Moreover, the partnership agreement with companies is expected to increase in number of clinical trials for thalassemia in the near future.

The global thalassemia treatment market has been segmented as given below:

Treatment Type

  • Blood Transfusion
  • Chelation Therapy
  • Bone Marrow Transplantation
  • Others

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • ASEAN Countries
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Thalassemia Treatment Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Thalassemia Treatment Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Market Outlook
4.7. Pipeline of Thalassemia Treatment
4.8. Prevalence & Demography – Thalassemia Disease – by Region/Country
4.8.1. North America
4.8.2. Europe
4.8.3. Asia Pacific
4.8.4. Latin America
4.8.5. Middle East & Africa
4.9. Cost of Treatment-By Region/Country
4.9.1. North America
4.9.2. Europe
4.9.3. Asia Pacific
4.9.4. Latin America
4.9.5. Middle East & Africa
4.10. Prevalent Treatment Regimens – By Country/Region
4.10.1. Asia Pacific
4.10.2. Middle East & Africa
4.11. List of Major Hospitals for Thalassemia Treatment – By Region/ Country/State
4.11.1. North America
4.11.2. Europe
4.11.3. Asia Pacific
4.11.4. Latin America
4.11.5. Middle East & Africa
4.12. Regulatory Scenario, by Region
4.12.1. North America
4.12.2. Europe
4.12.3. Asia Pacific

Chapter 5. Global Thalassemia Treatment Market Analysis and Forecasts, by Treatment Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast, by Treatment Type, 2016–2026
5.3.1. Blood Transfusion
5.3.2. Chelation Therapy
5.3.3. Bone Marrow Transplant
5.3.4. Others
5.4. Market Attractiveness, by Treatment Type

Chapter 6. Global Thalassemia Treatment Market Analysis and Forecasts, by Region
6.1. Key Findings
6.2. Market Value Forecast, by Region
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East & Africa
6.3. Market Attractiveness, by Country/Region

Chapter 7. North America Thalassemia Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.2. Market Value Forecast, by Treatment Type, 2016–2026
7.2.1. Blood Transfusion
7.2.2. Chelation Therapy
7.2.3. Bone Marrow Transplant
7.2.4. Others
7.3. Market Value Forecast, by Country, 2016–2026
7.3.1. U.S.
7.3.2. Canada
7.4. Market Attractiveness Analysis
7.4.1. By Treatment Type
7.4.2. By Country

Chapter 8. Europe Thalassemia Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Treatment Type, 2016–2026
8.2.1. Blood Transfusion
8.2.2. Chelation Therapy
8.2.3. Bone Marrow Transplant
8.2.4. Others
8.3. Market Value Forecast, by Country/Sub-region, 2016–2026
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Spain
8.3.5. Italy
8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis
8.4.1. By Treatment Type
8.4.2. By Country/Sub-region

Chapter 9. Asia Pacific Thalassemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2016–2026
9.2.1. Blood Transfusion
9.2.2. Chelation Therapy
9.2.3. Bone Marrow Transplant
9.2.4. Others
9.3. Market Value Forecast, by Country/Sub-region, 2016–2026
9.3.1. China
9.3.2. India
9.3.3. ASEAN countries
9.3.4. Rest of Asia Pacific
9.4. Market Attractiveness Analysis
9.4.1. By Treatment Type
9.4.2. By Country/Sub-region

Chapter 10. Latin America Thalassemia Treatment Market Analysis and Forecast

……..

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112003/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi